ALT Two graphs showing the composite kidney end point (full analysis population). Panel A shows the least-squares mean change in the estimated glomerular filtration rate (eGFR) from baseline to 24 months, analyzed by the repeated-measures model, in the full analysis population, which included all patients who underwent randomization. Panel B shows the progression to a composite of kidney-function decline or kidney failure.

ALT A forest plot displaying the effectiveness of sibprernlimab versus placebo across various subgroups. Subgroups include demographic characteristics like age and race, as well as geographic region and stratification factors. Each subgroup is represented with bars indicating slope differences in ml/min/1.73 m² per year with 95% confidence intervals.

ALT A bar chart from the Original Article "Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.” The trial name, RAINIER AIS-D08, is in parentheses after the title. The chart shows change in 24-hr urinary protein-to-creatinine ratio at week 36. The trial results are being presented at the American Society of Nephrology Kidney Week 2026. The logo of the New England Journal of Medicine is at the bottom.